| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
ML 351 manufacturers
- ML351
-
- $48.00
-
2026-08-21
- CAS:847163-28-4
- Purity: 97.86%
- Supply Ability: 10g
|
| Product Name: | ML 351 | | Synonyms: | ML 351;5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile;4-Oxazolecarbonitrile, 5-(methylamino)-2-(1-naphthalenyl)-;Subarachnoid hemorrhage,inhibit,oxidative stress,ML-351,SAH,neuronal,Lipoxygenase,LOX,T1D,β-cell,ML 351,ML351,Inhibitor,non-obese diabetic;5-(Methylamino)-2-(naphthalen-1-yl)oxazole-4-carbonitrile;ML351, 10 mM in DMSO;12/15-Lipoxygenase Inhibitor, ML351;ML351 NEW | | CAS: | 847163-28-4 | | MF: | C15H11N3O | | MW: | 249.27 | | EINECS: | | | Product Categories: | | | Mol File: | 847163-28-4.mol |  |
| | ML 351 Chemical Properties |
| Boiling point | 507.3±60.0 °C(Predicted) | | density | 1.29±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | ≤5mg/ml in DMSO;25mg/ml in dimethyl formamide | | form | powder | | pka | -0.97±0.10(Predicted) | | color | white to beige | | InChI | 1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3 | | InChIKey | DYXYXTDIFMDJIR-UHFFFAOYSA-N | | SMILES | CNC1=C(C#N)N=C(O1)C2=C3C(C=CC=C3)=CC=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | ML 351 Usage And Synthesis |
| Description | Lipoxygenases (LOs) are non-heme iron-containing dioxygenases that catalyze the oxidation of polyunsaturated fatty acids to generate unsaturated fatty acid hydroperoxides. The immediate products of 15-LO fatty acid oxidation act as mediators in inflammation, thrombosis, and cancer. ML351 is an inhibitor of human reticulocyte 15-LO-1 (IC50 = 200 nM) with >250-fold selectivity over the related enzymes 5-LO, platelet 12-LO, 15-LO-2, ovine COX-1, and human COX-2. ML351 was shown to be protective against oxidative glutamate toxicity in mouse neuronal HT-22 cells and significantly reduced infarct size in an in vivo mouse model for ischemic stroke. | | Uses | ML351 is a selective 12/15 LOX inhibitor (IC50 = 200 nM). Exhibits >250-fold selectivity over related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. Protects against oxidative glutamate toxicity in mouse neuronal cells (HT-22) and reduces infarct size in a mouse ischemic stroke model. | | Biochem/physiol Actions | ML351 is a cell penetrant, selective and highly potent human lipoxygenase-12/15 (15-Lipoxygenase-1, 12/15-LOX) inhibitor that exhibits protective effects against oxidative glutamate toxicity in mouse neuronal HT22 cells. ML351 reduces infarct size in a mouse model of ischemic stroke. | | in vivo | ML351 (0-48 mg/kg; before the beginning of the STZ series and concluding 5 days after the last dose of STZ) protects against diabetes development in an STZ β-cell injury model. ML351 at 24 mg/kg (M24)+ STZ shows significantly less weight reduction compares with control group. M24 shows almost complete protection from hyperglycemia. But M48 and M0 exhibits frank hyperglycemia by day 9 of the study and significantly impaired GTTs[2].ML351 (intraperitoneal injection; 0-24 mg/kg; daily for 2 weeks) leads to improved glycemic control and significantly reduced insulitis. The reduction of β-cell death in NOD mice has been suggested to lead to reductions in insulitis, likely by mitigating the chemotactic signals released by dying β-cells. NOD + M24 animals exhibited improved glycemic control compared with NOD + M0 animals[2]. | Animal Model: | Nine-week-old male C57BL/6J mice[2] | | Dosage: | 0 mg/kg; 24 mg/kg; 48 mg/kg; | | Administration: | Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ | | Result: | Protected against diabetes development in an STZ β-cell injury model that mimics the inflammation seen in T1D. |
| Animal Model: | Female NOD mice develop spontaneous autoimmune diabetes between 12 and 24 weeks of age[2] | | Dosage: | 0 mg/kg; 24 mg/kg; 48 mg/kg; | | Administration: | Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ | | Result: | Protected Against Early Glycemic Deterioration in NOD Mice. |
| | storage | Store at -20°C | | references | [1]. rai g, joshi n, perry s, et al. discovery of ml351, a potent and selective inhibitor of human 15-lipoxygenase-1. probe reports from the nih molecular libraries program [internet]. bethesda (md): national center for biotechnology information (us); 2010-2013 apr 15 [updated 2014 jan 13].
[2]. rai g, joshi n, jung je, et al. potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. j med chem. 2014 may 22;57(10):4035-48.
[3]. gaffney bj. lipoxygenases: structural principles and spectroscopy. annu rev biophys biomol struct. 1996;25:431-59. |
| | ML 351 Preparation Products And Raw materials |
|